Cannabis Science, Inc. (CBIS.OB) announced that it now has the results of its survey of more than 1,300 individuals with post traumatic stress disorder or PTSD, including a large cohort of veterans. The survey was conducted by Cannabis Science Advisory Board member Mitch Earleywine of the State University of New York.
The company has reported several prospective drugs for FDA clinical trials. Based on extensive studies and this survey, the company now has the substantiated data to for its first application for a PTSD drug for FDA clinical trials. The company will now sign a pre-negotiated contract with a group of FDA specialists based in Colorado to handle the company's first FDA filings.
For comments and feedback: editorial@rttnews.com